Difficult-to-treat chronic rhinosinusitis-when the  standard treatment is not effective and biologics are not available

CONCLUSION: To accurately assess the efficacy of second-line therapies for treatment of difficult-to-treat CRS within an endotype-specific framework, additional controlled clinical trials are needed that take into account the heterogeneity of CRS endotypes.PMID:38472346 | DOI:10.1007/s00106-024-01443-w
Source: HNO - Category: ENT & OMF Authors: Source Type: research